ACP
NDRM

Acuta Capital Partners’s NeuroDerm Ltd. Ordinary Shares NDRM Stock Holding History

Acuta Capital Partners’s Portfolio NDRM Stock Details NDRM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-72,866
Closed -$2.18M – 89
2017
Q2 		$2.18M Sell
72,866
-377,134
-84% -$9.77M 0.61% 31
2017
Q1 		$11.9M Sell
450,000
-215,944
-32% -$5.35M 2.83% 10
2016
Q4 		$14.8M Buy
665,944
+202,988
+44% +$3.8M 5.5% 5
2016
Q3 		$8.56M Sell
462,956
-171,044
-27% -$2.96M 3.21% 8
2016
Q2 		$10.3M Sell
634,000
-192,799
-23% -$3.25M 4.95% 4
2016
Q1 		$11.7M Buy
826,799
+349,499
+73% +$4.72M 6.53% 5
2015
Q4 		$8.14M Sell
477,300
-19,330
-4% -$377K 3.89% 7
2015
Q3 		$10.3M Buy
496,630
+196,630
+66% +$4.03M 5.94% 3
2015
Q2 		$4.61M Buy
300,000
+196,833
+191% +$2.77M 2.85% 9
2015
Q1 		$1.39M Buy
+103,167
New +$1.27M 1.17% 26

Other funds holding NDRM

AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return
SAM
Sandell Asset Management New York $179M AUM 65.55% 1-Year Est. Return
OP
Omni Partners London, United Kingdom $2.03B AUM 126.33% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
OAM
Oxford Asset Management Oxford, United Kingdom $232M AUM 31% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return
CFIC
City Financial Investment Company London, United Kingdom $562M AUM 5.93% 1-Year Est. Return
WIC
Water Island Capital New York $896M AUM 107.59% 1-Year Est. Return
FTCM
First Trust Capital Management Chicago, Illinois $1.9B AUM 58.39% 1-Year Est. Return

Acuta Capital Partners's NDRM Position: Q3 2017 in Review

Acuta Capital Partners sold out of NeuroDerm Ltd. Ordinary Shares (NDRM) in Q3 2017, closing a stake of 72,866 shares — an estimated $2.18M sold.

Acuta Capital Partners first reported a position in NDRM in Q1 2015 and held it in 10 quarters. The position peaked at $14.8M in Q4 2016. 81 funds tracked by Wall St. Rank hold NDRM as of Q3 2017.

  • Acuta Capital Partners reported no remaining NeuroDerm Ltd. Ordinary Shares position as of Q3 2017 after selling out during the quarter.
  • Acuta Capital Partners sold 72,866 NeuroDerm Ltd. Ordinary Shares shares in Q3 2017, an estimated $2.18M.
  • Acuta Capital Partners first reported a position in NeuroDerm Ltd. Ordinary Shares in Q1 2015 and held it in 10 quarters.
  • Acuta Capital Partners's NeuroDerm Ltd. Ordinary Shares position peaked at $14.8M in Q4 2016.
  • 81 funds tracked by Wall St. Rank held NeuroDerm Ltd. Ordinary Shares as of Q3 2017.

Based on Acuta Capital Partners's 13F filing for Q3 2017, filed 14 Nov 2017.